Peptides for Psoriasis and Eczema

Psoriasis and atopic eczema (dermatitis) are among the most common chronic skin conditions in the UK, and both involve immune dysregulation that has made them targets for peptide and biologic therapy.

Psoriasis: - Affects approximately 1.8 million people in the UK (2–3% of the population) - An autoimmune condition characterised by rapid skin cell turnover - Manifests as red, scaly, raised patches (plaques) typically on elbows, knees, scalp, and lower back - Associated with psoriatic arthritis (up to 30% of patients), cardiovascular disease, metabolic syndrome, and depression - Severity ranges from mild (limited plaques) to severe (widespread, debilitating disease)

Atopic eczema (dermatitis): - Affects approximately 5–10% of UK adults and up to 20% of children - A chronic inflammatory skin condition characterised by dry, itchy, inflamed skin - Results from a combination of genetic barrier defects (filaggrin mutations) and immune dysregulation (Th2 inflammation) - Severity ranges from mild dry patches to severe, widespread inflammation requiring hospitalisation - Major impact on sleep quality, mental health, and quality of life

Why people with these conditions explore peptides: - Chronic conditions with periods of flare and remission - Standard topical treatments (steroids, calcineurin inhibitors) have limitations and side effects - Severe disease may not respond adequately to topical treatment alone - Interest in skin barrier repair and "healing" approaches - Topical peptide skincare products are widely marketed for skin health - Some of the most effective treatments for severe psoriasis are already peptide-based biologics

The key insight: Peptide-based treatments are already revolutionising severe psoriasis and eczema management through biologic therapies. Understanding the full landscape — from cosmetic peptides to prescription biologics — helps contextualise where different peptide options fit.

Some of the most effective treatments for moderate-to-severe psoriasis and eczema are biologic medications that target specific peptide signalling pathways.

For psoriasis (available on the NHS through NICE-approved pathways):

1. Anti-TNF biologics: - Adalimumab (Humira/biosimilars): Fortnightly injection - Etanercept (Enbrel/biosimilars): Weekly injection - Infliximab (Remicade/biosimilars): IV infusion every 8 weeks - These target TNF-alpha, a pro-inflammatory cytokine

2. Anti-IL-17 biologics: - Secukinumab (Cosentyx): Monthly injection - Ixekizumab (Taltz): Monthly injection - Bimekizumab (Bimzelx): Monthly injection - IL-17 is a key driver of psoriatic inflammation

3. Anti-IL-23 biologics: - Guselkumab (Tremfya): Every 8 weeks - Risankizumab (Skyrizi): Every 12 weeks - Tildrakizumab (Ilumetri): Every 12 weeks - These target the IL-23 pathway upstream of IL-17

4. Anti-IL-12/23: - Ustekinumab (Stelara): Every 12 weeks

For eczema:

1. Dupilumab (Dupixent): Anti-IL-4/IL-13 biologic, available on NHS for moderate-to-severe eczema 2. Tralokinumab (Adtralza): Anti-IL-13, NICE-approved 3. JAK inhibitors: Baricitinib (Olumiant), abrocitinib (Cibinqo), upadacitinib (Rinvoq) — oral tablets targeting intracellular signalling

The significance: These biologic treatments achieve 75–90% skin clearance in many patients with severe disease. They represent the most successful application of peptide-pathway targeting in dermatology. Many patients achieve near-complete clearance of their psoriasis or eczema — outcomes that were unimaginable 20 years ago.

Access through the NHS: NICE has approved these biologics for patients with moderate-to-severe disease who have failed conventional systemic treatments. Prescribing is through specialist dermatology services. Waiting times for dermatology vary but are typically 3–6 months in the UK.

GHK-Cu (copper peptide) is the topical peptide most frequently discussed for inflammatory skin conditions. Here is what the evidence shows.

GHK-Cu research:

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide that declines with age. It has documented biological activities relevant to skin health:

• •Collagen synthesis: GHK-Cu stimulates collagen type I and III production, improving skin structure and integrity
• •Anti-inflammatory effects: GHK-Cu has been shown to reduce expression of pro-inflammatory cytokines including IL-6 and TNF-alpha in skin models
• •Antioxidant properties: Promotes superoxide dismutase (SOD) production, reducing oxidative stress in skin
• •Wound healing: Multiple studies show accelerated wound healing in both animal and limited human studies
• •Skin remodelling: Promotes both breakdown of damaged collagen and synthesis of new collagen

Relevance to psoriasis: - The anti-inflammatory properties are theoretically relevant - Skin barrier improvement could benefit psoriatic skin - However, psoriasis is primarily a systemic autoimmune condition, and topical peptides are unlikely to address the underlying immune dysregulation - No clinical trials have evaluated GHK-Cu for psoriasis - At best, it might provide modest complementary benefit alongside proven treatments

Relevance to eczema: - Eczema involves skin barrier dysfunction, and GHK-Cu's collagen-stimulating and barrier-supporting properties are theoretically beneficial - Anti-inflammatory effects could complement emollient therapy - Wound healing promotion could help with excoriated (scratched) skin - No clinical trials for eczema specifically - The copper component may cause contact sensitisation in some individuals

Other topical peptides marketed for skin conditions: - Palmitoyl pentapeptide-4 (Matrixyl): Collagen stimulation, anti-wrinkle. No evidence for psoriasis or eczema - Acetyl hexapeptide-3 (Argireline): Muscle relaxation for expression lines. Irrelevant to inflammatory skin conditions - Carnosine: Antioxidant peptide with limited skin research - Antimicrobial peptides (LL-37, defensins): Naturally occurring skin defence peptides. Research is exploring synthetic versions for skin infections and inflammatory conditions, but no products are yet available

The reality: Topical peptides are cosmetic ingredients with modest benefits for general skin health. They are not treatments for psoriasis or eczema and should not be presented as such.

BPC-157 has some research relevant to skin inflammation and wound healing, though it is limited and preclinical.

Animal research on BPC-157 and skin:

• •Wound healing studies: BPC-157 has accelerated skin wound healing in rat models, with improved collagen deposition, angiogenesis, and reduced time to closure
• •Burn healing: Rat studies show improved healing of skin burns with BPC-157 administration
• •Anti-inflammatory effects in skin models: Reduced inflammatory markers in various skin injury models

Relevance to psoriasis and eczema:

The research is tangentially relevant at best: - Psoriasis is driven by IL-17/IL-23 pathway dysregulation. There is no evidence that BPC-157 modulates these specific pathways - Eczema involves Th2 immune polarisation and barrier dysfunction. BPC-157's effects on these specific mechanisms are unknown - The wound healing data may be relevant to excoriated eczema or cracked psoriatic skin, but this has not been studied

Route of administration questions: - Systemic administration (subcutaneous injection) — unclear whether sufficient BPC-157 reaches the skin to exert effects - Topical administration — limited data on skin penetration. BPC-157 is a peptide and may not penetrate intact skin barrier effectively - Some users create topical preparations from reconstituted BPC-157. There are no data on stability, penetration, or efficacy of such preparations

Our assessment of BPC-157 for skin conditions: - The evidence is insufficient to recommend use for either psoriasis or eczema - Proven biologic treatments exist that target the specific immune pathways driving these conditions - The risk-benefit analysis is unfavourable: unproven benefit vs contamination risk, cost, and lack of safety data - For mild disease, proven topical treatments (emollients, steroids, calcineurin inhibitors) are more appropriate - For moderate-severe disease, biologic therapies through NHS dermatology are transformatively effective

The BPC-157 skin application context: Some people use BPC-157 not specifically for psoriasis or eczema but for general skin healing (cuts, scars, post-procedure healing). The animal wound healing data provides a theoretical rationale, but human evidence is absent.

Understanding the established treatment pathways ensures you access the most effective options before considering unproven alternatives.

Psoriasis treatment ladder (NHS):

1. Mild psoriasis (80% of patients): - Emollients (moisturisers) as the foundation - Topical corticosteroids (short courses) - Vitamin D analogues (calcipotriol, tacalcitol) - Coal tar preparations - Combination products (e.g. Enstilar — calcipotriol + betamethasone)

2. Moderate psoriasis: - Phototherapy (UVB) — available through dermatology departments - Topical combinations as above

3. Moderate-to-severe psoriasis: - Conventional systemics: Methotrexate, ciclosporin, acitretin, fumaric acid esters - Apremilast (PDE4 inhibitor)

4. Severe psoriasis (biologics): - The biologic options listed in the previous section - NICE-approved, available through specialist dermatology

Eczema treatment ladder (NHS):

1. Mild eczema: - Emollients (generous, frequent application — the cornerstone of eczema management) - Mild topical corticosteroids (hydrocortisone 1%)

2. Moderate eczema: - Moderate-potent topical corticosteroids - Topical calcineurin inhibitors (tacrolimus, pimecrolimus) - Topical crisaborole (PDE4 inhibitor) - Bandage therapy

3. Severe eczema: - Phototherapy - Systemic immunosuppressants (ciclosporin, methotrexate, azathioprine) - Biologic therapy (dupilumab, tralokinumab) - JAK inhibitors (baricitinib, abrocitinib, upadacitinib)

Accessing specialist dermatology in the UK: - GP referral to NHS dermatology: Waiting times 3–12 months depending on area and urgency - 2-week-wait pathway available for suspected skin cancer - Private dermatology: £150–£350 per consultation, much faster access - Teledermatology services are expanding, improving access

The critical message: If you have moderate-to-severe psoriasis or eczema, modern biologic treatments can be genuinely life-changing. These are evidence-based peptide-pathway treatments available through the NHS. Pursuing unproven research peptides instead of accessing specialist dermatology care is not a reasonable approach.

*This article is for educational purposes only. Psoriasis and eczema require medical assessment and management. See your GP or dermatologist for personalised treatment advice.*